Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 133

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 133
---
 which could be the products upon which our business depends. 

If we fail to comply with our obligations under any
potential future license agreement, including the payment of all amounts due under these potential agreements, we may lose the rights
to developed and potentially commercialize the underlying technology, and the licensor may have the right to terminate the license agreement
or restrict our rights upon notice, in which event we would not be able to develop or market products covered by the agreement, which
could be the products upon which our business depends. For instance, on May 4, 2022, we entered into a License Agreement with CWRU allowing
us to develop and commercialize our former lead product candidate, MIE-101. On March 22, 2024, we received a notice of termination from
CWRU terminating the License Agreement due to our inability to pay amounts owed to CWRU in accrued patent fees due to our limited cash
position.

If we successfully identify new product candidates
and license those rights, we may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could
be expensive, time consuming and unsuccessful. 

Because competition in our industry is intense, competitors
may infringe or otherwise violate potential rights to patents of our licensors or other intellectual property that we may license or acquire
in the future. If we are able to raise sufficient capital and potentially license or acquire new technologies, in order to counter infringement
or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against
perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition,
in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe
the patent’s claims narrowly, or refuse to stop the other party from using the technology at issue on the grounds that our patents
do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our potential patents
at risk of being invalidated or interpreted narrowly. We may also elect to enter into license agreements in order to settle patent infringement
claims or to resolve disputes prior to litigation, and any such license agreement may require us to pay royalties and other fees that
could be significant. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation,
there is a risk that some of our